News

Members of the Bcl-2 family of proteins have long been known to facilitate cancer cell survival. Nevertheless, it has proven difficult to disrupt their function using traditional small

Findings from the trial, named EXPRESS II, showed that Remicade (infliximab) maintenance therapy every eight weeks resulted in greater long-term skin clearance compared with ‘as-needed’ therapy regimens within

The FDA approved Xyrem (sodium oxybate) in July 2002 as the first and only treatment for cataplexy in patients with narcolepsy. In November 2005, the FDA approved Xyrem

Vivaglobin recently became the first and only FDA-approved subcutaneous immunoglobulin (Ig) treatment and can be safely self-administered by primary immunodeficiency (PI) patients under a physician’s care in the

Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. The potential of

The phase II pagoclone trial enrolled approximately 130 patients and will be the largest controlled pharmaceutical trial ever conducted in stuttering. The trial is an eight-week, double-blind, placebo-controlled

CC-10004 is a novel, orally available small molecule with anti-inflammatory activities that inhibits the production of multiple proinflammatory mediators including PDE-4, TNF-alpha, interleukin-2 (IL-2), interferon-gamma, leukotrienes, and nitric

Cortex undertook this phase IIa clinical trial to assess both the dose of drug required and the effectiveness of CX717 in an adult ADHD population. The primary outcome

The new drug application (NDA) for TMC114 is based on the efficacy and safety results from the 24-week analysis of two randomized, controlled studies, POWER 1 and POWER